Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Perez Losada, Jesus ^a,b   Wu, Di ^a   DelRosario, Reyno ^a   Balmain, Allan ^a   Mao, Jian Hua ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SUSCEPTIBILITY; FBXW7 GENE; FEMALE; GENE; GENE DELETION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERM LINE; LYMPHOMA; MOUSE; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR; TUMOR SUPPRESSOR GENE; ANIMAL; GENETIC PREDISPOSITION; GENETICS; MUTATION; NEOPLASM;

ANIMALIA; MUS;

F BOX PROTEIN; FBXW7 PROTEIN, MOUSE; PROTEIN P53; UBIQUITIN PROTEIN LIGASE;

ALLELES; ANIMALS; F-BOX PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; LYMPHOMA; MICE; NEOPLASMS; SEQUENCE DELETION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84856927324     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031301     Document Type: Article

References (38)

1. Balmain A, (2002) Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 108: 145-152.
2. Balmain A, Gray J, Ponder B, (2003) The genetics and genomics of cancer. Nat Genet 33 (Suppl): 238-244.
3. Mao JH, Balmain A, (2003) Genomic approaches to identification of tumor-susceptibility genes using mouse models. Curr Opin Genet Dev 13: 14-19.
4. Galvan A, Ioannidis JP, Dragani TA, (2010) Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 26: 132-41.
5. Stadler ZK, Thom P, Robson ME, Weitzel JN, Kauff ND, et al. (2010) Genome-Wide Association Studies of Cancer. J Clin Oncol 28: 4255-67.
6. Perez-Losada J, Castellanos-Martín A, Mao JH, (2011) Cancer Evolution and Individual Susceptibility. Integrative Biology, 3: 316-328.
7. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. (2009) Finding the missing heritability of complex diseases. Nature 461: 747-753.
8. Nagase H, Mao JH, de Koning JP, Minami T, Balmain A, (2001) Epistatic interactions between skin tumor modifier loci in interspecific (spretus/musculus) backcross mice. Cancer Res 61: 1305-8.
9. Tripodis N, Hart AA, Fijneman RJ, Demant P, (2001) Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 93: 1484-91.
10. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, et al. (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34: 403-412.
11. Nagase H, Mao JH, Balmain A, (2003) Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res 63: 4849-4853.
12. Li FP, Fraumeni JF Jr, (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43: 1365-1373.
13. Knudson AG Jr, (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823.
14. Hienonen T, Salovaara R, Mecklin JP, Järvinen H, Karhu A, Aaltonen LA, (2006) Preferential amplification of AURKA 91A (Ile31) in familial colorectal cancers. Int J Cancer 118: 505-508.
15. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, et al. (2004) Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumor suppressor gene. Nature 432: 775-779.
16. Perez-Losada J, Mao JH, Balmain A, (2005) Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res 65: 6488-6492.
17. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, et al. (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23: 2116-2125.
18. Welcker M, Orian A, Jin J, Grim JA, Harper JW, et al. (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A 101: 9085-9090.
19. Nateri AS, Riera-Sans L, Da Costa C, Behrens A, (2004) The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303: 1374-1378.
20. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, et al. (2001) Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294: 173-177.
21. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK, (2001) Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413: 311-316.
22. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, et al. (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413: 316-322.
23. Wu G, Lyapina S, Das I, Li J, Gurney M, et al. (2001) SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol 21: 7403-7415.
24. Oberg C, Li J, Pauley A, Wolf E, Gurney M, et al. (2001) The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 276: 35847-35853.
25. Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, et al. (2001) Functional interaction between SEL-10, an F-box, and the nuclear form of activated Notch1 receptor. J Biol Chem 276: 34371-34378.
26. Fujii Y, Yada M, Nishiyama M, Kamura T, Takahashi H, et al. (2006) Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci 97: 729-736.
27. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, et al. (2008) FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321: 1499-1502.
28. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, et al. (2009) Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69: 8967-8976.
29. Welcker M, Clurman BE, (2008) FBW7 ubiquitin ligase: a tumor suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93.
30. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-7.
31. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, et al. (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-9012.
32. Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, Ishida N, et al. (2004) Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem 279: 9417-9423.
33. Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, et al. (2004) Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A 101: 3338-3345.
34. Nagase H, Bryson S, Cordell H, Kemp CJ, Fee F, et al. (1995) Distinct genetic loci control development of benign and malignant skin tumors in mice. Nat Genet 10: 424-429.
35. Nagase H, Mao JH, Balmain A, (1999) A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc Natl Acad Sci U S A 96: 15032-7.
36. Mao JH, Wu D, Perez-Losada J, Nagase H, DelRosario R, et al. (2003) Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene 22: 8379-8385.
37. Ginzinger DG, Godfrey TE, Nigro J, Moore DH 2nd, Suzuki S, et al. (2000) Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 60: 5405-5409.
38. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158: 1253-1262.